Background: High-grade malignant mixed adenoneuroendocrine carcinoma (MANEC) is a highly malignant combined neoplasm formed by an adenocarcinomatous component and a poorly differentiated (Grade 3) neuroendocrine (NE) carcinoma. Methods: Tumors from 21 patients with gastrointestinal high-grade malignant MANECs or tumors with varying percentages of Grade 3 NE component were examined, and the NE component was confirmed by morphological analysis and immunohistochemical staining. Patients were divided into high NE (NE component > 50% in the primary tumor) and low NE (NE component 50% in the primary tumor) component groups. Results: High NE component was a poor prognostic factor for patients with high grade MANEC ( p ¼ 0.021). Out of 13 patients with high-grade malignant MANEC, eight had a pure NE component, one had a pure adenocarcinomatous component, and four had mixed-type cancer in the metastatic lymph nodes. We further enrolled eight patients who had a Grade 3 NE component in the primary tumor and found that the pure NE component in tumor emboli and distant liver metastases were more frequent in the high NE than in the low NE component group ( p ¼ 0.012 and p ¼ 0.046, respectively). Conclusion: The predominant tumor component in primary tumors was a prognostic factor and could predict tumor emboli and liver metastases pathology in high-grade malignant MANECs.
Introduction
Human cancers with a combination of neuroendocrine (NE) and exocrine features are known to occur in various organs such as the prostate, 1 breast, 2,3 colon, 4 stomach, 5e8 and lungs. 9 This spectrum of tumors shows mixed divergent differentiation along NE and exocrine lineages; these two components exhibit variable proportion, ranging from 1% to 99%. From these Conflicts of interest: The authors declare that there are no conflicts of interest related to the subject matter or materials discussed in this article.
tumors, mixed adenoneuroendocrine carcinomas (MANECs) are defined as malignant tumors characterized by morphologically recognizable gland-forming epithelial and NE components, with at least 30% of either component being present in the tumor, according to the World Health Organization (WHO) classification of endocrine tumors of the digestive system. 10 MANECs are very rare cancers, 11, 12 and can be divided into low, intermediate, and high grades of malignancy. The optimal strategy for managing MANEC is unknown, due to the rarity of these neoplasms. In general, MANECs containing a lowgrade NE tumor component and an adenocarcinomatous component should be treated as adenocarcinoma. 13e15 Tumors containing a high-grade NE component should be treated as NEC. 13e15 It is interesting that the extent of these two components in primary tumors and lymph nodes is not always the same. 5, 6 One report presented a case of gastric MANEC, in which the neoplastic signet-ring cell exocrine and NE components occurred in fairly equivalent amounts, with only the NE carcinoma portions of the tumor detected in the metastatic lymph nodes. 5 Distant metastasis to vital organs is the main cause of death from cancer. Thus, it is worth investigating the tumor components in the lymph nodes and distant metastases of patients with MANEC, which may help clinicians to adopt different treatment strategies.
In this study, we retrospectively enrolled 13 patients with high-grade malignant MANEC and observed the pathology of the primary tumor, tumor emboli, lymph nodes, and distant liver metastases. Eight patients had a pure NE component, one patient had an adenocarcinomatous component, and four patients had a mixed-type cancer in the metastatic lymph nodes. We further enrolled another eight patients who had a Grade 3 NE component in the primary tumor. Of the eight patients, the proportion of the NE component was > 70% in five patients, and < 30% in three patients. We identified that the high NE component in the primary tumor was a factor for poor prognosis and also could predict the pathology of tumor emboli and distant liver metastases in high-grade MANECs.
Methods

Patient clinicopathological data
This study was approved by the Ethics Committee of the Taipei Veterans General Hospital, Taipei, Taiwan and the National Taiwan University Hospital, Taipei, Taiwan. Clinical data and pathological data were obtained through a detailed retrospective review of the medical records for 13 patients with MANEC between 2000 and 2010 at the Taipei Veterans General Hospital and the National Taiwan University Hospital. All patients underwent surgery. The median age of the patients was 76 years (range, 55e84 years). The origin of the primary tumor differed between patients; the primary tumor site was the stomach in nine patients, the colon in three, and the gall bladder in one. Follow-up data were available in all cases, and the duration of follow-up was 0.8e49.7 months (median, 15.9 months; mean, 18.6 months). The last survival data were collected on December 31, 2013. We also enrolled another eight patients whose tumors had Grade 3 NE components. The percentage of the NE component was > 70% in five patients and < 30% in three patients. The characteristics of 21 cases are summarized in Table 1 .
Immunohistochemical staining
Hematoxylin and eosin staining results of all 21 samples were reviewed by two pathologists. The specimens were fixed in formalin and embedded in paraffin before they were archived. We used the archived specimens for immunohistochemical analysis. Immunohistochemical staining was performed with Bond-Max autostainer (Leica Microsystems, Wetzlar, Germany), using CD56 (NCL-CD56-1B6, clone 1B6; 1:15; Novocastra/Leica, Newcastle-upon-Tyne, UK), chromogranin (NCL-CHROM-430, clone 5H7; 1:50; Novocastra/ Leica), synaptophysin (NCL-SYNAP-299, clone 27G12; 1:50; Novocastra/Leica), and neuron-specific enolase (BBS/NC/VI-H14; 1:200; Dako, Carpinteria, CA, USA). Briefly, specimens from the paraffin-embedded blocks were cut into 5-mm sections. The sections were dewaxed in a 60 C oven, deparaffinized in xylene, rehydrated through serial dilutions of alcohol, and washed in phosphate-buffered saline (pH 7.2). Immunohistochemical staining was performed in the fully automated Bond-Max autostainer using onboard, heat-induced antigen retrieval in citrate buffer according to the ER1 protocol for 20 minutes and a VBS Refine polymer detection system (Leica Microsystems). Diaminobenzidine was used as the chromogen (Leica Microsystems). The sections were then counterstained with hematoxylin.
Evaluation of the NE component in primary tumors, tumor emboli, lymph nodes, and distant liver metastases
The percentage of the NE component in primary tumors, status of tumor spreading, and the tumor component in tumor emboli, lymph nodes or liver metastases were evaluated by two pathologists. In primary tumors, the NE component was confirmed by morphology and positive immunohistochemical staining for two of the four NE markers (CD56, chromogranin, synaptophysin, and neuron-specific enolase).
For tumors found in tumor emboli, lymph nodes, and liver metastases, the NE component was confirmed by morphology alone, the results of which were then compared with that of primary tumors. Cases of adenocarcinoma showing focal NE differentiation were identified only by immunostaining and not by morphological differences; amphicrine tumors thus identified were excluded from the study.
Statistical analysis
We divided the patients into two groups: the high NEcomponent group (n ¼ 13; defined by an NE component of > 50% in the primary tumor) and the low NE-component group (n ¼ 8; defined by an NE component of 50% in the primary tumor). The association between the proportion of NE component in primary tumors and in tumor emboli or lymph node or distant liver metastases was analyzed for statistical significance using the Chi-square test. Survival data were analyzed according to the KaplaneMeier method. The log-rank test was used to compare survival data between groups. A p value of < 0.05 was considered significant.
Results
High NE components in primary MANEC was associated with poor prognosis
Univariate overall survival analysis was performed to test the prognostic significance of clinical variables in 21 MANEC cases, and only NE components in primary tumor was shown to have an adverse impact on survival ( p ¼ 0.021; Table 1 and Fig. 1 ). Our data indicate that high NE components in primary tumor predicted a poor prognosis in terms of high-grade MANEC.
Pathology of tumors involved in tumor emboli was similar to that in metastatic lymph nodes and distant liver metastases
Of the 21 patients, 20 had tumor emboli, 17 had metastatic lymph nodes, and four had distant liver metastases. Pure NE sections in tumor emboli were observed in 13 patients, pure adenocarcinoma was observed in four patients, and both components were observed in three patients (Table 2) . In most cases, the components of lymph node metastases and distant liver metastases were similar to those of tumor emboli; only two patients had different components (Cases 2 and 9, Table 2 ).
Therefore, the tumor components involved in tumor emboli may suggest the pathology of metastatic lymph nodes and distant liver metastases (Table 2) Table 3 ). In cases of tumor emboli, 91.7% (11/12) of patients in the high NE group had a pure NE component in their tumors, whereas 50% (4/8) of patients in the low NE group had a pure adenocarcinomatous component. In cases of distant liver metastases, 100% (3/3) of patients in the high NE group had a pure NE component in their tumors, whereas 100% (1/1) of patients in the low NE group had a pure adenocarcinomatous component. From these results, we observed that tumor emboli and distant liver metastases with a pure NE component were observed more frequently in the high NE component group than in the low NE component group ( p ¼ 0.012 and p ¼ 0.046; Table 3 ).
Increased percentage of pure NE-component tumors in lymph nodes in high NE component group
In cases of lymph nodes, 81.8% (9/11) of patients in the high NE component group showed pure NE-component tumors in their lesions of lymph nodes, whereas 33.3% (2/6) of patients in the low NE component group showed pure adenocarcinomatous component tumors. These data show that pure NE-component tumors in lymph nodes showed more of a trend in the high NE component group than in the low NE component group ( p ¼ 0.065; Table 3 ).
Discussion
Gastrointestinal MANECs can be stratified into three different prognostic categories according to the grade of each component's malignancy. 16 High-grade malignant MANEC is a highly malignant combined neoplasm formed by an adenomatous (villous or tubulovillous) or carcinomatous (adenocarcinoma or squamous cell carcinoma) component, together with a poorly differentiated (Grade 3) NEC. 15 The optimal treatment strategy for high-grade malignant MANEC is unknown because of the rarity of the disease. When considering treatment, the more aggressive component of MANECs should be taken into account. MANEC containing a well differentiated NET (Grades 1 or 2) component and an adenocarcinoma Table 2 The relationship between the pathology of tumor emboli, regional lymph node, and distant liver metastasis.
Case
NE component (%) Ki67 Diagnosis WHO grading of adenocarcinoma Tumor emboli Lymph nodes Distant liver metastasis component should be treated as adenocarcinoma. MANEC containing a poorly differentiated NEC (Grade 3) component should be treated as NEC, 13e15 although this recommendation lacks enough evidence to support it. In our study, 75% (3/4) of patients with high-grade malignant MANEC had a pure NE component and 25% (1/4) had a pure adenocarcinomatous component in distant liver metastases. Distant metastasis to vital organs is the main cause of death from cancer. Thus, it is reasonable to identify the tumor components in the distant metastatic tumor of patients with MANEC, which may help clinicians develop new treatment strategies.
In 1987, Lewin 2 presented a method for classifying mixedtype adenoneuroendocrine carcinomas according to three separate patterns: (1) the exocrine and endocrine areas are admixed within the same tumor mass and constitute at least one-third of the tumor; (2) concurrent NE and exocrine differentiation are exhibited by the same tumor cells, i.e., amphicrine tumors; and (3) the exocrine and endocrine areas are juxtaposed, but not admixed within the same tumor mass. 2 This study defined the criteria for determining the extent of the NE component in mixed-type adenoneuroendocrine carcinomas as 30%, which incidentally, is the same as that currently used. 2, 10 However, the significance of the NE component in MANEC is unclear and has received limited clinical attention. 11 In this study, we wanted to investigate the role of NE component in these patients. Thus, we recruited an additional eight patients (3 patients with NE < 30% and 5 patients with NE > 70%) with varying NE components. We enrolled a total of 21 patients with a poorly differentiated (Grade 3) NEC component, at various percentages ranging from 10% to 90%. We found that a high NE component (> 50%) in the primary tumor was associated with poor prognosis. This phenomenon is also observed in prostatic adenocarcinomas with NE differentiation, which shows that the NE component is a negative prognostic factor. 17, 18 We also found high NE component increased rate of pure NE component tumors in tumor emboli and distant liver metastases (Table 3) . The tumor components of the distant metastases should be the main factor that affects tumor progression. However, it is sometimes difficult to obtain tissue samples from metastatic lesions. In this situation, the results of our study lead us to suggest that the pathology of metastatic lesions can be determined by observing the components present in tumor emboli or the percentage of the NE component in the primary tumor.
A high NE component was associated with an adverse outcome and increased rate of pure NE component in distant liver metastases. The negative prognostic value of a high NE component of high-grade gastrointestinal MANECs might be due to the clinical course of these diseases being more likely to be pure poorly differentiated NE carcinomas. 19 Most gastrointestinal MANECs generally show nuclear immunoreactivity for CDX2. However, some reports also showed CDX2 also expressed in small number of lung NE carcinomas. 20, 21 In addition, La Rosa et al 20 further subdivided colorectal MANEC into four groups according to CDX2, TTF1, and ASH1 expression. The expression of these transcription factors does not show a prognostic significance, but their expression is interesting because it indicates the phenotypical heterogeneity of the neuroendocrine component of gastrointestinal MANEC. Another interesting issue is the possible mechanisms of two different components of cancer cells coexisting in one tumor. There are two major hypotheses: these tumors might arise independently from different stem/ progenitor cells, or they might derive from a common, multipotent stem/progenitor cell. 13, 15 Recently, Scardoni et al 22 used next-generation sequencing to assess 54 cancerassociated genes in patients with MANECs. Both the exocrine and neuroendocrine components of six MANECs were microdissected and analyzed. They found that five of the six MANECs presented an overlapping mutational profile in both components. The result suggested two different components from the same stem/progenitor cell. Neuron-specific enolase and chromogranin A are both biomarkers of neuroendocrine neoplasms that have potential to predict the outcome or monitor the treatment response. However, the relationship of these biomarkers in MANEC is still not clear. It warrants further studies in the future.
The main limitation of this study is its small sample size (n ¼ 21). Also, MANEC is a very rare malignancy, and most patients are diagnosed with distant metastases. Both of the reasons mentioned above cause difficulties in the collection of samples for analysis. Further studies are required to validate the role of NE components in high-grade malignant MANEC.
In conclusion, we found that the extent of NE and adenocarcinomatous components in primary high-grade malignant MANECs and their metastatic tumors are not always the same. Furthermore, the NE component of tumors involved in tumor emboli was similar with that in lymph node and distant liver metastases. A high NE component in the primary tumor predicted a poor prognosis and increased the rate of pure NE component tumors in tumor emboli or distant metastases. These data may assist clinicians in deciding the appropriate treatment method for patients with high-grade malignant MANEC.
